Version history

{
  "session_id": "sess_hypdebate_h_b662ff65_20260427_112802",
  "round_number": 2,
  "agent_persona": "persona-skeptic",
  "content": "\n\n# Critical Evaluation: Stathmin-2 Splice Switching Hypothesis\n\n## Core Mechanistic Concerns\n\nThe hypothesis presents a coherent molecular pathway, but conflates correlation with causation. While TDP-43 mislocalization is established across ALS-FTD-AD, the assertion that STMN2 depletion is the *primary* driver of axonal degeneration remains unproven. TDP-43 regulates hundreds of splicing targets (Klim et al. 2019 mapped extensive networks), and STMN2 dysregulation may represent one of many downstream effectors rather than the critical linchpin. Restoration of a single splicing target may prove insufficient if axonal degeneration stems from cumulative loss of multiple TDP-43 functions.\n\nThe mechanistic logic also contains internal tension. Stathmin-2 is characterized as a microtubule-destabilizing protein—yet its depletion would logically *stabilize* microtubules, contrary to the proposed therapeutic rationale. The hypothesis would benefit from clarifying whether axonal vulnerability reflects stathmin-2's specific signaling functions beyond microtubule dynamics.\n\n## Alternative Explanations\n\nMultiple non-mutually-exclusive mechanisms could explain axonal degeneration in TDP-43 proteinopathy: stress granule sequestration of TDP-43 functional pools, cytoplasmic aggregation causing proteostatic stress, impaired mitochondrial trafficking, and direct disruption of mRNA transport to axons. The therapeutic prediction that splice switching will halt degeneration assumes the splicing axis is dominant—a significant assumption without causal demonstration.\n\n## Methodological Limitations\n\niPSC-derived neuron models capture early disease but lack the decades-long pathological evolution in human CNS. Rodent STMN2 splice regulation differs from humans, and species-specific validation may not translate. ASO delivery to ventral horn motor neurons and cortical neurons in human trials remains a substantial pharmacological challenge—achieving therapeutically relevant CNS concentrations is not guaranteed.\n\n## Missing Evidence\n\nCritical gaps include: (1) lack of post-mortem studies demonstrating STMN2 protein depletion correlates with axonal degeneration *in vivo*, (2) no human trial data showing ASO-mediated STMN2 restoration halts clinical progression, and (3) inadequate characterization of whether PTBP1 upregulation in human diseased tissue follows the proposed mechanism. Biomarker correlations (NfL) are descriptive, not mechanistic validation.\n\nThe hypothesis is scientifically credible and"
}